.png)
Frameworks, core principles and top case studies for SaaS pricing, learnt and refined over 28+ years of SaaS-monetization experience.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
What Discounting Rules Make Sense for Multi Year Pharmacy SaaS Deals
A pharmacy SaaS contract is not merely a software purchase. It is a commitment around systems that support prescription flow, access control, audit trails, patient data, controlled-substance workflows, and increasingly drug-traceability processes. CMS has set January 1, 2028, as the date when Part D e-prescribing must exclusively use NCPDP SCRIPT Version 2023011. DEA rules require identity proofing and two-factor authentication for electronic prescribing of controlled substances. HIPAA requires appropriate safeguards for electronic protected health information.
That operating reality changes the discounting question. A buyer wants price stability because switching is risky. A seller can be tempted to exchange a deep discount for a long signature because renewal feels likely. Both instincts are incomplete. Monetizely's position is that pharmacy SaaS vendors should offer a three-year term as a disciplined price-certainty program: 4% off for two years, 7% off for three years with annual payment, and 10% only for full prepayment. Discounts should apply to a firm per-location platform commitment, not to implementation, new modules, or uncertain transaction volume.
A pharmacy buyer is not buying continuity for its own sake. It is buying lower operational risk. Yet a multi-year agreement can create a different risk if the vendor has underpriced the work required to maintain integrations, compliance features, security controls, and support through regulatory change.
The distinction matters because several pharmacy technology obligations are moving on a fixed timetable. CMS allows a transition from NCPDP SCRIPT Version 2017071 to Version 2023011 through December 31, 2027, then requires exclusive use of Version 2023011 for covered Part D e-prescribing beginning January 1, 2028. FDA has also extended certain DSCSA exemptions for qualifying small dispensers through November 27, 2027.
A discount program should therefore pay for commercial certainty while preserving the vendor's ability to fund the product work that keeps customers compliant.
Exhibit 1: Pharmacy obligations make continuity valuable, but they do not make every future feature free
| Operating condition | Current requirement or date | What the contract should cover | What the contract should not silently include |
|---|---|---|---|
| Part D e-prescribing standards | CMS requires exclusive use of NCPDP SCRIPT Version 2023011 from January 1, 2028. (cms.gov) | Standard updates required to keep the contracted e-prescribing function supported | A newly released workflow product or separately priced interoperability module |
| Controlled-substance prescribing | DEA guidance, current as of September 3, 2026, requires identity proofing and two-factor authentication credentials for EPCS. (deadiversion.usdoj.gov) | Maintenance of the contracted EPCS capability and standard security patches | Customer-specific identity-provider work, custom device deployment, or remediation caused by a customer configuration |
| Patient data security | HHS states that the HIPAA Security Rule requires administrative, physical, and technical safeguards for ePHI. (hhs.gov) | Security updates, audit logging, and contracted availability commitments | Open-ended security consulting, forensic work, or custom controls outside the standard product |
| Drug-traceability readiness | FDA's current small-dispenser exemption can run through November 27, 2027 for qualifying pharmacies. (fda.gov) | Product maintenance for an already purchased traceability module | Future DSCSA products that add a new data network, workflow, or paid service |
The commercial implication is direct: core compliance maintenance belongs in the base subscription, while newly created products and customer-specific work require separate pricing.
The 5-Step Pricing Framework puts discounting in its proper place. It starts with Goals and Segmentation: clarify whether the business needs faster adoption, stronger retention, higher margins, or a better position in a defined customer segment. It then moves to Packaging, which determines the features, services, and terms appropriate for each segment. Pricing Metric follows, answering what the customer will actually be charged for. Only then does the company set Price Points. Finally, Operationalizing turns the design into quoting rules, billing logic, approvals, and renewal processes. As Monetizing Agentic AI argues, this sequence prevents a price concession from becoming a substitute for a pricing strategy.
For pharmacy SaaS, the framework leads to a firm conclusion. Discounting is a Step 4 decision, but the right discount is determined by the first three steps. A three-year deal cannot repair a package that bundles unwanted modules, a metric that customers cannot forecast, or a segment strategy that treats an independent pharmacy and a 300-location chain as the same buyer.
Exhibit 2: The five decisions turn a contract term into a pricing rule
| Framework step | Decision for pharmacy SaaS | Consequence for multi-year discounting |
|---|---|---|
| Goals and Segmentation | Separate independents, regional chains, and enterprise operators by buying process, rollout pattern, and required controls | Do not offer one discount schedule to every segment |
| Packaging | Put core dispensing operations, standard support, and required product updates in the platform package; sell specialized workflows as modules | Discount the core package, not every item on the order form |
| Pricing Metric | Use an active dispensing location as the primary meter | Tie the committed minimum to locations, not a vague promise of enterprise growth |
| Price Points | Set a published two-year and three-year rate card | Give sales a defined give-get exchange rather than a discretionary range |
| Operationalizing | Put minimums, true-ups, price-lock rules, and exception approvals in CPQ and renewal playbooks | Make the policy executable without executive intervention on routine deals |
The framework points to one central discipline: a seller should not discount what it cannot count, forecast, bill, and defend.
Named-user pricing looks simple, but it is usually the wrong primary commitment for pharmacy operations. Staffing changes. Technicians rotate across shifts. A pharmacist may be temporarily absent. A central support team may need access to several stores. None of those changes alters the basic value the pharmacy receives from the platform operating at a dispensing site.
An active dispensing location is more durable. It reflects where the customer relies on the software to support daily pharmacy work. A five-store regional chain should commit to five operating sites, even if its authorized user count changes from 30 to 44 during the contract term.
That does not mean every capability should be priced per location. The architecture should be clear:
- Core platform: recurring fee per active dispensing location, with a reasonable bundle of authorized users.
- Optional modules: separate recurring fee per location when a module supports a distinct workflow, such as patient engagement, prior-authorization operations, or traceability.
- Variable services: usage bands or true-ups for activity that varies materially, such as message volume, transaction volume, or document processing.
- Implementation: a separate fixed-fee or time-and-materials statement of work, never discounted simply because the subscription term is longer.
A primary location meter makes the contract understandable for finance, useful for sales, and stable for the buyer. It also prevents a familiar failure mode: a vendor gives a three-year concession on a broad “enterprise” license, then discovers that a rollout has doubled in scope without a matching increase in revenue.
The broader SaaS market offers a useful lesson. Vendors do not treat a multi-year commitment as a reason to discount every part of the bill. They define a minimum commitment, distinguish annual payment from monthly flexibility, and preserve a path for added usage or seats.
Exhibit 3: Public SaaS offers show the building blocks, not a pharmacy discount benchmark
The common pattern is not “discount deeply for duration.” It is “trade a defined commitment for a defined economic benefit.”
Monetizely recommends a simple standard schedule. It is intentionally narrower than the 15% to 25% concessions often requested in enterprise negotiations. Pharmacy SaaS has meaningful retention potential, but that fact is already reflected in the product's value and implementation burden. A long term does not erase the cost of support, roadmap delivery, cloud infrastructure, security, or regulatory maintenance.
Exhibit 4: A disciplined discount schedule for pharmacy SaaS
| Term and payment structure | Standard discount on committed platform and existing modules | Required give from the customer | Vendor give |
|---|---|---|---|
| One year, paid annually | 0% | Annual commitment to the stated locations and modules | Standard price for the subscription year |
| Two years, paid annually | 4% | Non-cancelable two-year minimum for the committed locations | Fixed unit price for committed scope through the term |
| Three years, paid annually | 7% | Non-cancelable three-year minimum, annual payment in advance, annual true-up for added locations | Fixed unit price for committed scope through the term |
| Three years, fully prepaid | 10% | Full subscription payment at signing for all three years | Fixed unit price for committed scope plus the cash-flow benefit of prepayment |
| Variable usage, regardless of term | 0% rate discount | A forecast or committed usage floor if the vendor chooses to offer one | Published volume bands and transparent true-up mechanics |
| Implementation, migration, custom integration, or training | 0% | Defined scope, milestones, and change-order process | Delivery commitments, not price concessions |
The schedule makes the economic exchange visible: annual payment earns a modest term discount, while full prepayment earns the only deeper concession.
A three-year buyer also receives a price lock. That benefit should be explicit because it has real budget value. The vendor should not obscure it by granting both a deep discount and an open-ended right to add any future product at the old rate. New modules should carry the then-current list price, though they may be co-termed with the existing agreement.
A price schedule becomes credible when both parties can see what it means over the full term. Consider a pharmacy SaaS deployment with a $72,000 annual recurring subscription at list price. The model below compares annual renewals with 5% yearly price increases against the recommended fixed-price multi-year options.
Exhibit 5: Three-year cost comparison for a $72,000 annual subscription
| Commercial path | Year 1 | Year 2 | Year 3 | Three-year cost | Savings versus annual renewals |
|---|---|---|---|---|---|
| Renew annually with 5% annual increase | $72,000 | $75,600 | $79,380 | $226,980 | - |
| Three years, paid annually, 7% discount and price lock | $66,960 | $66,960 | $66,960 | $200,880 | $26,100, or 11.5% |
| Three years, prepaid, 10% discount and price lock | $194,400 paid at signing | - | - | $194,400 | $32,580, or 14.4% |
The buyer receives meaningful certainty without requiring the seller to give away a fifth of the account's value.
A seller should also make clear what this model excludes. The subscription price lock covers the committed package. New stores, added modules, unusual transaction growth, custom development, and expanded implementation work remain separately priced. The customer gains a known rate where certainty exists; the vendor retains a fair price where scope remains uncertain.
The hard cases are predictable. A strategic chain may want a 15% concession. A new buyer may request a three-year contract while still unsure whether its first rollout will succeed. A procurement team may ask for termination for convenience while also demanding a price lock. Those are not standard multi-year commitments.
The approval process should ask whether the buyer has removed enough uncertainty to earn the discount.
Exhibit 6: Exceptions should be decided by commitment quality
| Buyer request | Commercial reading | Standard response |
|---|---|---|
| Three-year term with termination for convenience | The vendor has not received a three-year revenue commitment | Offer annual pricing or remove the termination right |
| Three-year deal for a phased rollout with unknown store count | The location minimum is not yet defined | Contract the initial operating sites; price future sites at a co-termed expansion rate |
| Deep discount in exchange for a reference call or case study | Marketing value does not fund product delivery or reduce collection risk | Keep the subscription discount unchanged; offer a separate, limited marketing consideration if warranted |
| Discount on implementation because the buyer signs for three years | Services effort is incurred early and remains sensitive to scope | Hold implementation pricing; use a milestone-based scope and change-order process |
| Customer asks for new modules at the old contracted rate | Future product value and delivery cost are unknown | Co-term new modules, but charge current list price or a published expansion rate |
| Large transaction forecast with no minimum spend | The buyer has not committed to the variable value it expects to receive | Use usage bands and an annual true-up, not a discounted unlimited-use promise |
The strongest policy protects sales teams as much as it protects margin. Reps should not have to invent a financial theory every time a buyer asks for a concession. They need a clear rule that says what a customer must give to receive a lower rate.
Several requests should never qualify as a substitute for a real commitment:
A disciplined program gives pharmacy buyers what they most need: a predictable operating cost for a platform they cannot casually replace. It gives the SaaS provider a fair exchange: durable revenue, clearer capacity planning, and less renewal friction. Neither side benefits from a low starting price that later produces surprise invoices, underfunded support, or a contentious renegotiation.
Monetizely's position remains clear: make the per-location platform fee the primary committed meter; make three years the standard long-term offer; cap the annual-pay discount at 7%; reserve 10% for full prepayment; and protect variable usage, implementation, and future modules from automatic discounting.
What operators should do next:
Measure discount quality by cohort, not by closed-won rate. Track gross retention, expansion, support cost, implementation margin, and collections for annual, two-year, and three-year cohorts. A discount rule is working only if the contracted revenue is also durable and profitable.
Give finance ownership of a three-year price book. Sales should quote from published rates, while finance reviews the annual economic impact of every nonstandard concession. That governance prevents one large deal from quietly resetting the market price.
Build a pharmacy-specific renewal narrative. Show buyers the value of price stability against known deadlines such as the January 1, 2028, NCPDP SCRIPT transition, rather than framing the term as a favor requested by the vendor. (cms.gov)
Separate product roadmap decisions from contract negotiations. Decide which compliance updates belong in the core subscription before a major deal reaches procurement. Sales should never promise future product scope to compensate for a discount request.
Use the first ten three-year deals as a controlled test. Review each deal after implementation and again at the first anniversary. If customers consistently buy more locations or modules than the commitment predicted, revise the package and expansion rules rather than widening the discount band.
Footnotes
- Monetizing Agentic AI. https://www.amazon.com/Monetizing-Agentic-AI-Handbook-Transformation/dp/B0H7Z13VKJ/
- Centers for Medicare & Medicaid Services, “E-Prescribing,” current requirements checked September 3, 2026. (cms.gov)
- U.S. Drug Enforcement Administration, “Electronic Prescriptions for Controlled Substances Q&A,” current guidance checked September 3, 2026. (deadiversion.usdoj.gov)
- U.S. Department of Health and Human Services, “Summary of the HIPAA Security Rule,” current guidance checked September 3, 2026. (hhs.gov)
- U.S. Food and Drug Administration, “Exemptions under the Drug Supply Chain Security Act,” current guidance checked September 3, 2026. (fda.gov)
- Adobe, “VIP Marketplace Three-Year Commit Amendment,” terms checked September 3, 2026. (adobe.com)